| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
FTISADTSK acetate is a signature peptide derived from Trastuzumab and does not itself bind to a biological receptor with therapeutic activity. It is a proteolytic fragment released upon tryptic digestion of the monoclonal antibody Trastuzumab. Its utility is as a quantitative biomarker for Trastuzumab in bioanalytical assays rather than as a direct modulatory agent targeting a specific cellular receptor.
|
|---|---|
| ln Vitro |
In vitro, FTISADTSK acetate is not studied for independent bioactivity such as receptor binding or enzyme inhibition. The peptide is used as an analytical standard in LC-MS/MS assays for quantifying Trastuzumab in biological samples. After tryptic digestion of Trastuzumab, FTISADTSK is liberated as a signature peptide and is detected by SRM to calculate antibody concentrations with high specificity and sensitivity.
|
| ln Vivo |
In vivo studies are not performed with this peptide itself as it is an ex vivo analytical tool. The unlabeled parent antibody Trastuzumab is used in vivo, where it binds to the HER2/neu receptor on cancer cells, inhibits receptor dimerization, and induces antibody-dependent cell-mediated cytotoxicity (ADCC). FTISADTSK acetate enables the quantitative measurement of Trastuzumab in patient samples for pharmacokinetic studies.
|
| Enzyme Assay |
FTISADTSK is used as an analyte for LC-MS/MS method development. For quantitative assays, prepare calibration standards by spiking known concentrations of FTISADTSK acetate into blank biological matrix. Add a fixed concentration of the 13C- and 15N-labeled internal standard (FTISADTSK-13C6,15N2) to each sample. Separate on a C18 reverse-phase column using a gradient elution. Detect using multiple reaction monitoring (MRM) on a triple quadrupole mass spectrometer. Calculate concentrations based on the peak area ratio relative to the internal standard.
|
| Cell Assay |
For cell uptake studies, treat HER2-positive cancer cells (e.g., SK-BR-3) with Trastuzumab (1-100 ug/mL) for 24-72 hours. Harvest cells, wash to remove unbound antibody, lyse cells, and digest cell lysates with trypsin. Add FTISADTSK acetate as an external standard if not using labeled internal standard. Quantify the signature peptide by LC-MS/MS to determine the amount of internalized Trastuzumab. Perform proper controls including untreated cells and cells treated with isotype control antibodies.
|
| Animal Protocol |
Animal studies are not performed with FTISADTSK acetate itself. For PK studies, administer Trastuzumab to mice or rats via intravenous injection at 1-10 mg/kg. Collect blood at multiple time points (0-336 hours). Prepare plasma, digest proteins with trypsin, and add stable isotope-labeled internal standard. Analyze by LC-MS/MS, monitoring the FTISADTSK signature peptide to quantify Trastuzumab concentrations. Calculate PK parameters such as Cmax, terminal half-life, AUC, clearance, and volume of distribution.
|
| ADME/Pharmacokinetics |
The acetate salt form of FTISADTSK is an analytical peptide standard and is not studied for pharmacokinetic properties. Trastuzumab (Herceptin) has a typical half-life of 5-25 days in humans following intravenous administration, with a clearance of approximately 0.1-0.2 L/day. Distribution is primarily within the vascular space. The peptide standard should be stored as a lyophilized powder at -20degC and protected from light. Reconstitute in water or appropriate buffer before use.
|
| Toxicity/Toxicokinetics |
FTISADTSK acetate is an analytical standard and is considered safe for laboratory use under standard chemical safety guidelines. The compound is not intended for human consumption. The acetate salt may cause mild irritation to eyes, skin, and respiratory tract. Standard laboratory precautions including gloves, lab coat, and safety glasses should be used. No genotoxicity or carcinogenicity data are available. This compound is not classified as hazardous for transport.
|
| References | |
| Additional Infomation |
FTISADTSK acetate is a research-grade peptide for in vitro and ex vivo bioanalytical use only. It is not approved for diagnostic or therapeutic applications. The peptide is derived from Trastuzumab (Herceptin), a humanized IgG1 monoclonal antibody targeting HER2/neu. Trastuzumab is approved for the treatment of HER2-positive breast cancer and gastric cancer. This peptide is typically used in combination with its stable isotope-labeled counterpart for accurate quantitation by LC-MS/MS.
|
| Molecular Formula |
C44H72N10O18
|
|---|---|
| Molecular Weight |
1029.10
|
| Related CAS # |
FTISADTSK;1431957-73-1
|
| Appearance |
White to light brown solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~48.59 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9717 mL | 4.8586 mL | 9.7172 mL | |
| 5 mM | 0.1943 mL | 0.9717 mL | 1.9434 mL | |
| 10 mM | 0.0972 mL | 0.4859 mL | 0.9717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
